

Printed as of 5/9/2025

Disclosures

Personal Commercial (23)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
AstraZeneca Pharmaceuticals	Research/Research Grants	Significant (>= \$5,000)	General Cardiology
Baron and Bud	Other - Expert Witness	Significant (>= \$5,000)	General Cardiology
Bayer	Research/Research Grants	Significant (>= \$5,000)	
Bayer	Consultant Fees/Honoraria	Significant (>= \$5,000)	Other
Cleveland Clinic	Consultant Fees/Honoraria	Modest (< \$5,000)	General Cardiology
Haemonetics	Research/Research Grants	Significant (>= \$5,000)	General Cardiology
Haemonetics	Research/Research Grants	Significant (>= \$5,000)	Other
Hikari Dx	Research/Research Grants	Significant (>= \$5,000)	General Cardiology
Idorsia	Research/Research Grants	Significant (>= \$5,000)	Acute Coronary Syndromes
Instrumentation Labs	Research/Research Grants	Significant (>= \$5,000)	
Janssen Pharmaceuticals, Inc	Consultant Fees/Honoraria	Modest (< \$5,000)	General Cardiology
Janssen Pharmaceuticals, Inc	Research/Research Grants	Significant (>= \$5,000)	Stable Ischemic Heart Disease
Janssen Pharmaceuticals, Inc	Research/Research Grants	Significant (>= \$5,000)	Stable Ischemic Heart Disease
LabCorp Drug Development	Research/Research Grants	Significant (>= \$5,000)	General Cardiology
Medforce	Consultant Fees/Honoraria	Modest (< \$5,000)	General Cardiology
Novartis Corporation	Research/Research Grants	Significant (>= \$5,000)	Stable Ischemic Heart Disease
Premier Health Care Resource	Consultant Fees/Honoraria	Modest (< \$5,000)	General Cardiology
Prolocor	Research/Research Grants	Modest (< \$5,000)	Acute Coronary Syndromes
Recor	Research/Research Grants	Significant (>= \$5,000)	Vascular Medicine
Recor Medical	Research/Research Grants	Significant (>= \$5,000)	General Cardiology
Vectura	Research/Research Grants	Significant (>= \$5,000)	General Cardiology
Web MD Medscape	Consultant Fees/Honoraria	Significant (>= \$5,000)	General Cardiology
Wolters Kluwer	Consultant Fees/Honoraria	Modest (< \$5,000)	General Cardiology

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (1)

Year Case Title Represented Description Compensation

Year	Case Title	Represented	Description	Compensation
Self				
2019	Clopidgrel	Third Party	Clopidogrel	Significant (>= \$5,000)

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 9/26/2024

URL for full agreement: http://disclosures. acc. org/Public/Definition/Certified EducationAttestationAgreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 9/26/2024

URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureand Assignment Agreement

Embargo | Signed on 9/26/2024

URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 9/26/2024

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.